Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEP-2 is a water-soluble polysaccharide fraction isolated from the rhizome of *Gastrodia elata* Blume, a plant widely used in traditional Chinese medicine. It is primarily characterized as a branched glucan with an α-D-glucose backbone and various monosaccharide substitutions, including galactose, rhamnose, and arabinose. Research indicates that GEP-2 possesses significant anti-inflammatory, antioxidant, and neuroprotective properties. In preclinical models of ulcerative colitis, it has been shown to alleviate symptoms by suppressing the NF-κB and STAT3 signaling pathways, reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and enhancing the intestinal barrier through the upregulation of tight junction proteins. Furthermore, GEP-2 modulates the gut microbiota, promoting the growth of beneficial bacteria such as *Dubosiella* and *Alistipes*. It also demonstrates neuroprotective effects by mitigating oxidative stress and inflammation in neuronal cells exposed to heavy metals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gastrodia elata polysaccharide GEP-2.